tiprankstipranks
Trending News
More News >
Diversified Healthcare Trust (DHC)
NASDAQ:DHC

Diversified Healthcare Trust (DHC) AI Stock Analysis

Compare
622 Followers

Top Page

DHC

Diversified Healthcare Trust

(NASDAQ:DHC)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - 5.2)
Rating:49Neutral
Price Target:
$6.00
â–¼(-2.44% Downside)
Action:ReiteratedDate:01/17/26
The score is held down primarily by weak financial performance—persistent losses, high leverage, and a sharp drop in recent cash generation—despite some deleveraging progress. Technicals are supportive due to a strong uptrend, but overbought indicators add near-term risk. Valuation is mixed: a very high yield helps, but negative earnings limit confidence in fundamentals. Earnings-call and recent corporate updates are directionally positive on liquidity and execution, yet leverage and transition-related cost pressure remain meaningful.
Positive Factors
Demographic-driven portfolio focus
DHC’s strategic focus on senior housing and medical office assets aligns with secular aging and healthcare demand trends, supporting durable occupancy and rental demand. This specialization tends to produce more predictable cash flows and tenant stickiness versus cyclical commercial segments.
Strong leasing and rent uplift in MOB/Life Sciences
Higher-quality, long-term leases with 9% rent uplift and nearly seven-year terms in medical office/life science assets lock in durable income growth and reduce vacancy risk. This enhances cash flow visibility and supports portfolio value through structural demand for specialized healthcare real estate.
Improving liquidity via capital recycling and refinancing
Active asset sales, operator transitions, and recent refinancing (no maturities until 2028) materially improve near-term liquidity and reduce immediate refinancing pressure. Sustained capital recycling can fund deleveraging and reposition the portfolio toward higher-return assets over the medium term.
Negative Factors
Very high leverage on adjusted EBITDA basis
A ~10x net debt/EBITDAre ratio materially increases financial risk, leaving limited cushion for earnings variability. High leverage amplifies refinancing and interest-rate exposure, constraining flexibility to invest, absorb operational shocks, or accelerate deleveraging without asset sales or equity issuance.
Weakened and volatile cash generation
Sharply reduced cash generation erodes the company’s ability to service debt, fund capex, or sustain distributions from operations. Historical volatility and prior negative operating cash flow episodes raise uncertainty around the durability of internally generated funds to support strategic objectives.
Persistent net losses and negative ROE
Ongoing net losses and negative returns on equity indicate the business has not yet converted revenue stability into profitability. This reduces retained capital, pressures NAV for a REIT, and limits the company’s ability to self-fund growth or materially improve leverage without external financing or portfolio restructuring.

Diversified Healthcare Trust (DHC) vs. SPDR S&P 500 ETF (SPY)

Diversified Healthcare Trust Business Overview & Revenue Model

Company DescriptionDHC is a real estate investment trust, or REIT, that owns medical office and life science properties, senior living communities and wellness centers throughout the United States. DHC is managed by the operating subsidiary of The RMR Group Inc., an alternative asset management company that is headquartered in Newton, MA.
How the Company Makes MoneyDHC makes money primarily through rental income from its diversified portfolio of healthcare properties. The company leases its properties to operators and tenants, generating a steady stream of revenue. Key revenue streams include long-term leases with established healthcare providers, which often include built-in rent escalations to ensure income growth over time. Additionally, DHC may benefit from strategic partnerships with healthcare operators that enhance property management efficiency and tenant retention. The company's financial performance is also influenced by market demand for healthcare services, occupancy rates, and the overall economic environment, which can impact rental pricing and property valuations.

Diversified Healthcare Trust Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Breaks down revenue by property type and service line—such as skilled nursing, assisted living, behavioral health, and management fees—showing which parts of Diversified Healthcare Trust generate the most cash. Reveals concentration risk, exposure to Medicare/Medicaid and private-pay mix, and whether occupancy or service demand trends are driving growth or decline.
Chart InsightsDHC has materially reshaped its portfolio mix—legacy Office revenue effectively exits the base starting in 2024 while Medical Office & Life Science ramps up, and SHOP has become the primary, steadily growing cash engine. Management’s leasing success and rising SHOP occupancy support this strategic pivot, but near-term NOI is pressured by operator transitions and elevated labor costs; successful asset sales and refinancing ease maturity risk, yet high leverage and transitional operating costs are the immediate watch points.
Data provided by:The Fly

Diversified Healthcare Trust Earnings Call Summary

Earnings Call Date:Feb 24, 2026
(Q4-2025)
|
Next Earnings Date:May 11, 2026
Earnings Call Sentiment Positive
The call presented a largely positive operational and financial narrative: strong NOI growth (+31.3% FY), meaningful SHOP performance improvement (Q4 SHOP NOI +27.6% YoY, same-store occupancy and rate gains, margin expansion), successful asset dispositions and deleveraging actions (net debt/EBITDAre down to 8.1x, no maturities until 2028), disciplined CapEx and robust liquidity. Challenges were acknowledged — integration/transition noise from the AlerisLife wind-down, remaining elevated leverage above target, pockets of underperforming SHOP assets being sold, and some near-term NOI headwinds in MOB/LS driven by prior sales. On balance the highlights substantially outweigh the lowlights, with clear operational levers and guidance that indicate continued improvement into 2026.
Q4-2025 Updates
Positive Updates
Strong Consolidated NOI Growth
Full-year consolidated NOI grew 31.3% in 2025, driven by operational execution and portfolio actions.
SHOP Segment Improvement
SHOP NOI for the quarter improved 27.6% year-over-year to $38.3M and full-year SHOP NOI was $139.3M (toward the high end of guidance). Same-property SHOP occupancy rose 90 bps YoY to 82.4%, average monthly rate increased ~5.8% YoY, and same-property SHOP NOI margins expanded 230 bps YoY.
Same-Property Cash NOI Momentum
Q4 same-property cash basis NOI was $70.4M, up 15.4% YoY and 12.4% sequentially. Consolidated same-property cash-basis NOI for Medical Office & Life Science increased 3.8% YoY with margins improving 100 bps to 59.6%.
Capital Markets and Deleveraging Progress
Completed over $1.4B of capital markets activity in 2025 (financing, asset sales, and a $150M undrawn credit facility). Net debt to adjusted EBITDAre declined from 11.2x (YE 2024) to 8.1x (YE 2025), and there are no debt maturities until 2028.
Asset Dispositions and Balance Sheet Actions
Sold 37 noncore properties in Q4 for ~$250M and 69 properties for ~$605M in 2025; proceeds fully repaid 2026 zero-coupon bonds and released 45 collateral properties with gross book value of ~ $850M.
Q4 Financial Results
Q4 total revenue $379.6M, adjusted EBITDAre $72.4M, normalized FFO $21.8M or $0.09 per share; full-year adjusted EBITDAre $284M (high end of guidance).
Liquidity and Cash Position
Ended quarter with approximately $255M of liquidity (including $105M unrestricted cash and $150M undrawn revolver). Subsequent $27.2M distribution received from AlerisLife wind-down.
MOB & Life Science Leasing Strength
Completed ~81,000 sq ft of leasing in Q4 at weighted average rents 7.9% above prior rents and average lease term >8 years. Leasing pipeline totals ~1.0M sq ft with average term ~6.9 years and GAAP rent spreads >10%.
CapEx Discipline
2025 capital spend totaled $146M (23% reduction vs 2024). 2026 recurring CapEx guidance of $100M–$115M (midpoint >18% decrease vs 2025), including $80M–$90M for SHOP and $20M–$25M for MOB/LS.
2026 Guidance and Outlook
2026 guidance: SHOP NOI $175M–$185M; MOB/LS NOI $94M–$98M; triple-net NOI $28M–$30M; adjusted EBITDAre $290M–$305M; normalized FFO $0.52–$0.58 per share. Management expects continued SHOP NOI improvement, lower interest costs, and lower CapEx to drive free cash flow growth.
Operational Upside Pipeline
Identified opportunity to reposition closed skilled nursing wings to add ~500 SHOP units with potential unlevered mid-teens ROI; estimated total capital to support these projects ~ $125M–$175M (timing multi-year).
Negative Updates
Transition Noise from AlerisLife Wind-Down
Transition of 116 communities to seven operators created operational 'noise' during the year; while largely completed, some transitions weighed on sequential top-line growth and required integration time for operators to realize full benefits.
Remaining Elevated Leverage
Net debt to adjusted EBITDAre remains elevated at 8.1x despite meaningful improvement from 11.2x, above management's target range of 6.5x–7.5x.
Underperforming SHOP Assets Marked for Sale
13 SHOP communities under agreement to sell for $23M (expected to close in March); these 13 properties lost $1.2M in Q4 and $3.0M for the full year, reflecting pockets of underperformance.
MOB/LS NOI Decline Driven by Sales
2026 expected decline in Medical Office and Life Science NOI largely driven by the sale of 31 properties that contributed $12.3M of NOI in 2025; 10.1% of annualized MOB/LS revenue scheduled to expire through 2026 with ~241k sq ft (~3.9% of annualized revenue) expected to vacate.
Interest Coverage Still Modest
Adjusted EBITDAre to interest expense improved to 1.5x in 2025 but remains modest; management expects coverage to be at or above 2.0x by year-end 2026, implying current vulnerability to interest cost volatility.
Dividend Uncertainty
Management indicated the Board will consider the dividend but there is no immediate priority to change it, leaving near-term clarity on dividend policy open for investors.
Company Guidance
On the call DHC gave 2026 guidance calling for SHOP NOI of $175–185 million, Medical Office & Life Science NOI of $94–98 million, and triple‑net senior living/wellness NOI of $28–30 million, supporting consolidated adjusted EBITDAre of $290–305 million and normalized FFO of $0.52–$0.58 per share; recurring CapEx is guided to $100–115 million (SHOP $80–90M, MOB/Life Science $20–25M, including ~$10M of refresh/ROI spend). Management noted liquidity of roughly $255 million (≈$105M unrestricted cash and $150M available on the revolver), no debt maturities until 2028, a year‑end 2025 net debt/adjusted‑EBITDAre of 8.1x (down from 11.2x), a near‑term leverage target of 6.5x–7.5x, and an expectation that adjusted‑EBITDAre/interest expense will be at or above 2.0x by year‑end 2026 (weighted‑average cash interest was 5.7% as of 12/31); the guidance also reflects operational momentum in SHOP (2025 SHOP NOI $139.3M, same‑property occupancy +90 bps to 82.4% in 2025 and roughly a 300‑bp full‑year occupancy improvement implied for 2026) and remaining opportunistic dispositions (13 properties under agreement for $23M).

Diversified Healthcare Trust Financial Statement Overview

Summary
Revenue is stabilizing/improving versus prior years, but fundamentals remain weak: persistent sizable net losses, meaningfully negative ROE, elevated leverage (debt-to-equity ~1.4+), and sharply lower recent operating/free cash flow versus 2024. Some debt reduction since 2022 is a positive, but cash-flow durability and balance-sheet risk are still key constraints.
Income Statement
32
Negative
Revenue has stabilized at a higher level in TTM (Trailing-Twelve-Months) (~$1.54B) versus 2024 (~$1.50B) and 2023 (~$1.41B), but profitability remains weak. Net losses are persistent and sizable (TTM net margin ~-19%; 2024 ~-25%; 2023 ~-21%), and operating-level performance is inconsistent year to year, suggesting limited earnings quality and a still-challenged operating model. A modestly improving gross margin trend from 2022 to TTM is a positive, but it has not translated into bottom-line profitability.
Balance Sheet
38
Negative
Leverage is elevated for a healthcare REIT, with debt running higher than equity (TTM debt-to-equity ~1.43; 2024 ~1.49), which reduces flexibility. Total debt has come down versus 2021–2022 levels, offering some balance-sheet progress, but returns on equity are meaningfully negative in recent periods (TTM ~-15%; 2024 ~-19%) due to ongoing losses. Overall, the balance sheet shows some deleveraging momentum, but still carries notable financial risk.
Cash Flow
29
Negative
Cash generation is a key concern: operating cash flow and free cash flow in TTM (Trailing-Twelve-Months) are positive but very low (~$18.7M) and down sharply versus 2024 (~$112M), indicating weaker cash profitability and/or working-capital pressure. While cash flow is currently positive, the magnitude is thin relative to the business size, and the volatility across years (including negative operating cash flow in 2021–2022) raises uncertainty around durability. The company is not consistently converting reported results into steady cash flow.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.54B1.50B1.41B1.28B1.38B1.63B
Gross Profit270.14M256.38M225.30M174.50M291.40M394.86M
EBITDA98.55M229.96M198.93M427.79M708.25M356.86M
Net Income-352.11M-370.25M-293.57M-15.77M174.51M-139.45M
Balance Sheet
Total Assets4.68B5.14B5.45B6.00B6.62B6.48B
Cash, Cash Equivalents and Short-Term Investments201.37M144.58M245.94M658.07M634.85M74.42M
Total Debt2.72B2.91B2.82B3.08B3.68B3.50B
Total Liabilities3.00B3.18B3.11B3.36B3.96B3.86B
Stockholders Equity1.69B1.96B2.34B2.64B2.66B2.50B
Cash Flow
Free Cash Flow18.69M112.22M10.48M-40.35M-63.32M158.54M
Operating Cash Flow18.69M112.22M10.48M-40.35M-63.32M158.54M
Investing Cash Flow210.02M-187.02M-202.11M387.71M242.70M-40.44M
Financing Cash Flow-280.48M-22.31M-249.71M-676.00M746.72M-79.48M

Diversified Healthcare Trust Technical Analysis

Technical Analysis Sentiment
Positive
Last Price6.15
Price Trends
50DMA
5.56
Positive
100DMA
4.99
Positive
200DMA
4.29
Positive
Market Momentum
MACD
0.24
Positive
RSI
53.95
Neutral
STOCH
12.93
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DHC, the sentiment is Positive. The current price of 6.15 is above the 20-day moving average (MA) of 6.14, above the 50-day MA of 5.56, and above the 200-day MA of 4.29, indicating a bullish trend. The MACD of 0.24 indicates Positive momentum. The RSI at 53.95 is Neutral, neither overbought nor oversold. The STOCH value of 12.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DHC.

Diversified Healthcare Trust Risk Analysis

Diversified Healthcare Trust disclosed 59 risk factors in its most recent earnings report. Diversified Healthcare Trust reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Diversified Healthcare Trust Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
$13.81B24.1011.79%6.11%13.50%31.56%
67
Neutral
$1.39B35.672.77%6.98%3.74%77.82%
65
Neutral
$2.17B12.193.79%4.94%3.15%1.96%
62
Neutral
$1.86B53.423.49%6.70%11.89%-68.41%
55
Neutral
$521.66M-145.240.49%10.01%2.73%-131.16%
49
Neutral
$1.61B-4.34-18.84%0.80%4.10%8.96%
* Real Estate Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DHC
Diversified Healthcare Trust
6.15
3.77
158.19%
LTC
LTC Properties
39.19
6.47
19.79%
OHI
Omega Healthcare
47.03
13.43
39.97%
GMRE
Global Medical REIT
35.90
-2.57
-6.68%
SILA
Sila Realty Trust, Inc.
25.60
2.96
13.07%

Diversified Healthcare Trust Corporate Events

Business Operations and Strategy
Diversified Healthcare Trust Gains Cash from AlerisLife Wind-Down
Positive
Jan 14, 2026

On January 9, 2026, Diversified Healthcare Trust received a cash dividend of $27.2 million from AlerisLife Inc. related to AlerisLife’s sale of all its assets and the wind-down of its business, and the company expects to receive an additional $3.0 million to $7.0 million upon completion of that wind-down, providing a notable cash inflow tied to the dissolution of this investment holding.

The most recent analyst rating on (DHC) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Diversified Healthcare Trust stock, see the DHC Stock Forecast page.

Business Operations and Strategy
Diversified Healthcare Trust Reshapes Senior Living Operations
Neutral
Jan 5, 2026

On December 31, 2025, Diversified Healthcare Trust completed the previously announced transition of management for 116 of its senior living communities from AlerisLife Inc. to seven different third-party operators, marking a significant reshaping of how this portion of its portfolio is run. As part of this shift, the company and AlerisLife mutually terminated their existing management agreements for these communities, signaling a strategic move to diversify operational oversight that may affect performance, risk distribution, and relationships with operating partners across its senior housing platform.

The most recent analyst rating on (DHC) stock is a Buy with a $6.50 price target. To see the full list of analyst forecasts on Diversified Healthcare Trust stock, see the DHC Stock Forecast page.

Business Operations and Strategy
Diversified Healthcare Trust Outlines 2025 Strategic Initiatives
Positive
Dec 8, 2025

On December 8, 2025, Diversified Healthcare Trust released an investor presentation outlining its strategic initiatives and financial outlook for 2025. The presentation highlighted DHC’s plans for capital recycling, operator transitions, and occupancy growth within its senior housing operating portfolio. It also emphasized the company’s focus on maintaining a strong liquidity position and leveraging favorable industry trends to enhance its market positioning. The strategic initiatives are expected to impact DHC’s operations positively, with potential implications for stakeholders in terms of improved financial performance and market competitiveness.

The most recent analyst rating on (DHC) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Diversified Healthcare Trust stock, see the DHC Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 17, 2026